Literature DB >> 3495208

C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin.

D R Morel, W M Zapol, S J Thomas, E M Kitain, D R Robinson, J Moss, D E Chenoweth, E Lowenstein.   

Abstract

The authors conducted a study in humans to determine the mediators associated with acute pulmonary vaso- and broncho-constriction occurring episodically with protamine reversal of heparin anticoagulation. Of 48 adult patients investigated prospectively after termination of cardiopulmonary bypass, two presented a sudden increase of airway pressure, acute pulmonary hypertension, and systemic hypotension 1-3 min after right atrial protamine injection. In these two subjects, plasma levels of C5a increased from 0.7 and 2.2 to 9.8 and 9.9 ng/ml, respectively, and thromboxane B2 increased from 0.26 and 0.34 to 7.5 and 16.2 ng/ml 1 minute after drug injection. A third subject not identified prospectively had an identical reaction and mediator profile (C5a, 10.2 ng/ml; TxB2, 18.6 ng/ml at 1 min). The plasma levels of these mediators were unchanged in the remaining patients (C5a, 0.7 +/- 1.1 [x +/- S.D.] to 0.6 +/- 0.9 ng/ml; TxB2, 0.16 +/- 0.12 to 0.15 +/- 0.07 ng/ml). Plasma histamine was not involved in this type of reaction, but increased from 0.7-10.4 ng/ml in a fourth patient who became hypotensive without acute pulmonary hypertension, bronchoconstriction, or elevation of C5a or TxB2. The authors' data indicate that the generation of high plasma levels of C5a anaphylatoxins and thromboxane is associated with pulmonary vaso- and broncho-constriction induced by protamine reversal of heparin in humans.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495208     DOI: 10.1097/00000542-198705000-00002

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  20 in total

1.  Complement activation during cardiac and thoracic vascular operations.

Authors:  P G Loubser
Journal:  Tex Heart Inst J       Date:  1987-12

2.  Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.

Authors:  Mercy O Quagraine; Fulong Tan; Hironori Tamei; Ervin G Erdös; Randal A Skidgel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

3.  Marked systemic hypotension accompanied by pulmonary hypertension following protamine reversal of heparin: Case report.

Authors:  Takashi Horiguchi; Keiji Enzan; Junichi Matsumoto; Mamoru Kadosaki; Masahiro Suzuki
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

4.  Ketanserin in the treatment of protamine-induced pulmonary hypertension.

Authors:  P J van der Starre; C Solinas
Journal:  Tex Heart Inst J       Date:  1996

5.  Impaired myocardial function and oxygen utilization due to protamine sulfate in an isolated rabbit heart preparation.

Authors:  T W Wakefield; L E Bies; S K Wrobleski; S F Bolling; J C Stanley; M M Kirsh
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

6.  The beneficial effects of aminophylline administration on heparin reversal with protamine.

Authors:  S F Katircioglu; D S Küçükaksu; M Bozdayi; K Dalva; B Mavitaş; Y Zorlutuna; O Taşdemir; K Bayazit
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

7.  Effects of protamine on histamine release from human lung.

Authors:  J H Levy; B A Faraj; J R Zaidan; V M Camp
Journal:  Agents Actions       Date:  1989-08

Review 8.  Allergy to protamine.

Authors:  M E Weiss; N F Adkinson
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 9.  Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator.

Authors:  Randal A Skidgel; Ervin G Erdös
Journal:  Int Immunopharmacol       Date:  2007-08-15       Impact factor: 4.932

10.  Carboxypeptidase N concentration during cardiopulmonary bypass in humans.

Authors:  S F Rabito; R Anders; W Soden; R A Skidgel
Journal:  Can J Anaesth       Date:  1992-01       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.